Can vasohibin-1, an endothelium-derived angiogenesis inhibitor, be a marker of endothelial dysfunction in hemodialysis patients?

Seminars in Dialysis
Orcun AltunorenOzkan Gungor

Abstract

Endothelial dysfunction (ED) is associated with high cardiovascular disease burden in hemodialysis (HD) patients. Vasohibin-1, an endothelium-derived angiogenesis inhibitor, is essential for endothelial cell survival, therefore it may be a promising marker of ED. We aimed to investigate whether vasohibin-1 levels are associated with ED markers in HD patients. Fifty HD patients and 30 healthy controls were included in the study. As markers of ED, endothelium-dependent flow-mediated dilatation (FMD), carotid intima-media thickness (CIMT), and pulse wave velocity (PWV) were examined. Serum vasohibin-1 levels were measured with ELISA. Serum vasohibin-1 levels were low (387.7 ± 115.7 vs 450.1 ± 140.1 P = .02), FMDs' were impaired (6.65 ± 2.50 vs 10.95 ± 2.86 P < .001), PWV (7.92 ± 1.964 vs 6.79 ± 0.96 P = .01) and CIMT (0.95 ± 0.20 vs 0.60 ± 0.11 P < .001) were increased in HD patients compared to healthy controls. In regression analysis, vasohibin-1 levels were not related with FMD, PWV, or CIMT. Hemodialysis patients have low serum vasohibin-1 levels but serum levels of vasohibin-1 did not show any significant relationship with FMD, PWV, and CIMT in HD patients. Since vasohibin-1 acts via paracrine pathways, serum levels may be in...Continue Reading

References

Feb 12, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·R JoannidesC Thuillez
Feb 7, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·M AnnukB Fellström
Jan 15, 2002·Journal of the American College of Cardiology·Mary C CorrettiUNKNOWN International Brachial Artery Reactivity Task Force
Jan 16, 2002·Circulation·Ian B WilkinsonJohn R Cockcroft
Feb 1, 2002·Journal of Hypertension·Alain SimonJaime Levenson
Jun 25, 2004·Advances in Chronic Kidney Disease·Gérard M LondonAlain P Guerin
Sep 24, 2004·The New England Journal of Medicine·Alan S GoChi-yuan Hsu
Mar 15, 2005·Scandinavian Journal of Urology and Nephrology·Qiang YaoPeter Stenvinkel
Jul 23, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Renu VirmaniJagat Narula
May 19, 2006·Biochemical and Biophysical Research Communications·Hiroshi YamashitaYasufumi Sato
Oct 2, 2008·Vascular Health and Risk Management·Mo Al-QaisiAnn E Donald
Mar 31, 2010·Hypertension·Ryan A HarrisRussell S Richardson
Jul 27, 2010·Blood Pressure Monitoring·Pascal M L Franssen, Ben P M Imholz
Jul 26, 2011·Clinical Journal of the American Society of Nephrology : CJASN·Francis H VerbekeGérard M London
Aug 8, 2012·Circulation·Andreas J FlammerAmir Lerman
Apr 7, 2015·Journal of Atherosclerosis and Thrombosis·Ryu FukumitsuSusumu Miyamoto
Jun 22, 2016·Aging Cell·Eichi TakedaYasufumi Sato
Jun 26, 2018·International Journal of Molecular Sciences·Katsuyuki TanabeJun Wada
Oct 4, 2018·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Mario CozzolinoAndrea Galassi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.